Specific allergen immunotherapy is viewed as a promising possibility for a successful atopic illness prevention strategy. The significant link between atopic symptoms like rhinitis and asthma and atopic sensitizations (specific serum IgE) provides justification for early management in infancy and adolescence. The evidence of disease-modifying intervention benefits is now restricted to the secondary prevention of asthma symptoms in children with allergic rhinoconjunctivitis. These effects appear to be allergen-specific rather than general.
Documentation on disease modification, including a reduction in asthma symptoms in children, has grown fairly substantial, notably with grass pollen pills. It is unclear if the new start of allergic sensitizations may be changed at this time. Data on primary prevention are inconclusive thus far.
